1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Cambodia and Laos Pharmaceuticals and Healthcare Report Q4 2016

Cambodia and Laos Pharmaceuticals and Healthcare Report Q4 2016

  • August 2016
  • -
  • Business Monitor International
  • -
  • 64 pages

Includes 3 FREE quarterly updates



BMI View: Cambodia is increasingly looking to provide greater health coverage for its population and thisbodes well for pharmaceutical firms over the longer term. However, consistently low levels of governmenthealth expenditure mean that there has been, and will continue to be, a lack of healthcare resourcesavailable for the development of the sector. Until the government shows more concrete commitment towardsthe sector, progress of healthcare provision to the population will be hindered.

Headline Expenditure Projections

- Pharmaceuticals: KHR1,008.1bn (USD250mn) in 2015 to KHR1,113.5bn (USD280mn) in 2016;+10.5% in local currency terms and US dollar terms. Forecast remains unchanged from previous quarter.

- Healthcare: KHR3,981.1bn (USD1.0bn) in 2015 to KHR4,181.1bn (USD1.1bn) in 2016; +5.0% in localcurrency terms and US dollar terms. Forecast remains unchanged from previous quarter.

Table Of Contents

Cambodia and Laos Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Cambodia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Cambodia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Cambodia 2012-2020) 17
Pharmaceutical Trade Forecast 18
Table: Pharmaceutical Trade Data And Forecasts (Cambodia 2014-2020) 19
Industry Risk/Reward Index 20
Asia Pacific Risk/Reward Index - Q4 2016 20
Cambodia Risk/Reward Index 27
Rewards 27
Risks 27
Regulatory Review 29
Intellectual Property Issues 29
Pricing And Reimbursement Regime 31
Market Overview 32
Healthcare Sector 32
Research and Development 35
Clinical Trials 36
Epidemiology 37
Competitive Landscape 40
Research-Based Industry 40
Table: Multinational Market Activity 42
Pharmaceutical Retail Sector 42
Pharmaceutical Distribution 44
Company Profile 45
Pfizer 45
PharmaProduct Manufacturing (PPM) 47
Sanofi 50
Demographic Forecast 53
Table: Population Headline Indicators (Cambodia 1990-2025) 54
Table: Key Population Ratios (Cambodia 1990-2025) 54
Table: Urban/Rural Population and Life Expectancy (Cambodia 1990-2025) 55
Table: Population By Age Group (Cambodia 1990-2025) 55
Table: Population By Age Group % (Cambodia 1990-2025) 56
Glossary 58
Methodology 60
Pharmaceutical Expenditure Forecast Model 60
Healthcare Expenditure Forecast Model 60
Notes On Methodology 61
Risk/Reward Index Methodology 62
Index Overview 63
Table: Pharmaceutical Risk/Reward Index Indicators 63
Indicator Weightings 64

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.